Document is current
Any future updates will be listed below
-
Authors
Hingorani, Dina V.
Allevato, Michael M.
Camargo, Maria F.
Lesperance, Jacqueline
Quraishi, Maryam A.
Aguilera, Joseph
Franiak-Pietryga, Ida
Scanderbeg, Daniel J.
Wang, Zhiyong
Molinolo, Alfredo A.
Alvarado, Diego
Sharabi, Andrew B.
Bui, Jack D.
Cohen, Ezra E. W.
Adams, Stephen R.
Gutkind, J. Silvio
Advani, Sunil J. https://orcid.org/0000-0002-7964-1315
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA215081, CA219744, P30CA23100)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | Center for Scientific Review (S10OD018499)
- License Information
-
More Information
Article History
Received: 14 June 2021
Accepted: 24 June 2022
First Online: 5 July 2022
Change Date: 1 August 2022
Change Type: Update
Change Details: In the original version of this article, the given and family names of J. Silvio Gutkind were incorrectly structured. The name was displayed correctly in all versions at the time of publication. The original article has been corrected.
Competing interests
: University of California San Diego has filed patent applications based on the findings described in this manuscript: “Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof” USPTO #10596259 (S.J.A.), “Tumor radiosensitization with antibody conjugates” US Patent Application No. 15/817,017 (S.R.A. and S.J.A.). The remaining authors declare no competing interests.
